Orthotopic Bone Regeneration within 3D Printed Bioceramic Scaffolds with Region-Dependent Porosity Gradients in an Equine Model
Diloksumpan, Paweena; Bolaños, Rafael Vindas; Cokelaere, Stefan; Pouran, Behdad; de Grauw, Janny; van Rijen, Mattie; van Weeren, René; Levato, Riccardo; Malda, Jos
(2020) Advanced Healthcare Materials, volume 9, issue 10, pp. 1 - 11
(Article)
Abstract
The clinical translation of three-dimensionally printed bioceramic scaffolds with tailored architectures holds great promise toward the regeneration of bone to heal critical-size defects. Herein, the long-term in vivo performance of printed hydrogel-ceramic composites made of methacrylated-oligocaprolactone-poloxamer and low-temperature self-setting calcium-phosphates is assessed in a large animal model. Scaffolds printed with
... read more
different internal architectures, displaying either a designed porosity gradient or a constant pore distribution, are implanted in equine tuber coxae critical size defects. Bone ingrowth is challenged and facilitated only from one direction via encasing the bioceramic in a polycaprolactone shell. After 7 months, total new bone volume and scaffold degradation are significantly greater in structures with constant porosity. Interestingly, gradient scaffolds show lower extent of remodeling and regeneration even in areas having the same porosity as the constant scaffolds. Low regeneration in distal regions from the interface with native bone impairs ossification in proximal regions of the construct, suggesting that anisotropic architectures modulate the cross-talk between distant cells within critical-size defects. The study provides key information on how engineered architectural patterns impact osteoregeneration in vivo, and also indicates the equine tuber coxae as promising orthotopic model for studying materials stimulating bone formation.
show less
Download/Full Text
Keywords: biofabrication, bone regeneration, equine models, low-temperature setting calcium phosphate, porous architectures, Biomaterials, Biomedical Engineering, Pharmaceutical Science
ISSN: 2192-2640
Publisher: John Wiley & Sons Inc.
Note: Funding Information: P.D. and R.V.B. contributed equally to this work. P.D. acknowledges the funding from the Royal Thai Government scholarship (Thailand). P.D., S.C., M.vR., J.dG., R.vW., R.L., and J.M. acknowledge the Dutch Arthritis Society (CO‐14‐1‐001, LLP‐12 and LLP‐22), and the European Research Council (grant agreement #647426, 3DJOINT). The primary antibodies against collagen type II (II‐II6B3) developed by T. F. Linsenmayer and E. S. Engvall, respectively, were obtained from the DSHB developed under the auspices of the NICHD and maintained by the University of lowa, Department of Biology, lowa City, IA, USA. Funding Information: P.D. and R.V.B. contributed equally to this work. P.D. acknowledges the funding from the Royal Thai Government scholarship (Thailand). P.D., S.C., M.vR., J.dG., R.vW., R.L., and J.M. acknowledge the Dutch Arthritis Society (CO-14-1-001, LLP-12 and LLP-22), and the European Research Council (grant agreement #647426, 3DJOINT). The primary antibodies against collagen type II (II-II6B3) developed by T. F. Linsenmayer and E. S. Engvall, respectively, were obtained from the DSHB developed under the auspices of the NICHD and maintained by the University of lowa, Department of Biology, lowa City, IA, USA. After initial online publication, J.M. was made a corresponding author on May 20, 2020. Publisher Copyright: © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
(Peer reviewed)